Piramal Enterprises acquire high potency API manufacturer in US

Piramal Enterprises to acquire high potency API manufacturer in US

6:51 AM, 17th August 2016
Piramal Enterprises to acquire high potency API manufacturer in US

MUMBAI, INDIA: Piramal Enterprises Limited (PEL) said that its wholly owned subsidiary in the US has entered into an agreement to acquire 100 percent stake in Ash Stevens Inc, a US based contract development and manufacturing organization (CDMO), in an all cash deal for a consideration of $42.95 million plus an earn-out consideration capped at $10 million. This potential transaction is expected to be completed by the end of August.

Located in Riverview, Michigan (US), Ash Stevens has over 50 years of experience in contract manufacturing, and serves several biotech, mid-size pharma, and large pharmaceutical clients worldwide.

With over 60,000 sq. ft. of facilities, eight chemical drug development and production laboratories, and six full-scale production areas, Ash Stevens has built a stellar reputation, led by science, driven by operational excellence, and one that emphasizes quality as a culture.

As one of the leaders in high potency API (HPAPI) manufacture, Ash Stevens has an impeccable safety record of working with high potency anti-cancer agents and other highly potent therapeutics. The state-of-the-art manufacturing facility in Michigan features all necessary engineering and containment controls for the safe handling and cGMP manufacture of small and large-scale HPAPIs, with occupational exposure limits (OELs) 0.1µg/m3. The facility has approvals from US, EU, Australia, Japan, Korea, Mexico regulatory agencies.

“The acquisition of Ash Stevens fits well with our strategy to build an asset platform that offers value to our partners and collaborators. Currently, around 25 percent of the molecules in clinical development are potent. Our clients are looking for reliable partners that can assist them in advancing these programs forward,” said Vivek Sharma, CEO of Piramal Pharma Solutions.

“Having facilities with a differentiated platform and geographical proximity to clients are keys towards building strategic partnerships. We expect this acquisition to also be synergistic with our antibody drug conjugates (ADCs) and injectable business. We can now fulfill client requirements for a single source of supply for both high potent APIs and drug products,” added Sharma.

“With its rich history of scientific excellence, a track record of 12 product launches, Ash Stevens is well poised to become the partner of choice for clients looking to advance programs from early development through launch.

“In addition to the business benefits that the combined entity will bring to our clients, I am also pleased that the firms share common core values: both were founded by successful entrepreneurs, value integrity, and are committed to a customer-first approach,” said Dr Mark Cassidy, president of the API business at Piramal.

“The commitment that Piramal has shown towards growing its healthcare businesses, coupled with the complementary capabilities that our two firms have, makes this an exciting time for Ash Stevens and our employees. We have already identified areas where we can create significant value together, and will be moving forward rapidly to achieve those objectives,” said Dr Stephen Munk, CEO of Ash Stevens.

Wells Fargo Securities LLC served as exclusive financial advisor to Ash Stevens, with legal counsel provided by Morrison & Foerster LLP.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Univar announces pricing of common stock for public offering

DOWNERS GROVE, US: Univar Inc has priced the previously announced public offering of 20,943,741 shares its common stock (representing approximately 15 ...

Read more
TerraVia, Nestle Purina to develop the next generation nutritious pet foods

SOUTH SAN FRANCISCO/ SAINT LOUIS, US: TerraVia Inc and Nestle Purina PetCare, a premiere global manufacturer of pet products have entered into a joint ...

Read more
2 killed, 3 injured after ammonia leak at Petronas fertiliser plant in Malaysia

KUALA LUMPUR, MALAYSIA: Two workers killed and three injured after a hazardous gas, ammonia leak at Petronas Chemicals Group Berhad’s plant in t ...

Read more
Wintershall, Engie, Gazprom, OMV, Shell, Uniper withdraws merger plan

KASSEL, GERMANY: Wintershall Holding GmbH, a wholly-owned subsidiary of BASF SE, Engie SA, Gazprom, OMV AG, Royal Dutch Shell plc and Uniper have deci ...

Read more
Scientists capture neon in an organic environment for the first time

CAMBRIDGE, UK: In a new study, researchers from the Cambridge Crystallographic Data Centre (CCDC) and the US Department of Energy’s (DOE’s ...

Read more
Researchers illuminate sulfides’ roles in the body

PULLMAN, US: For the first time, researchers at Washington State University (WSU) have created an injectable compound or probe that illuminates hydrog ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X